BioPharm America™ brings the world’s largest pharma companies to Boston

CARLSBAD, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Organized by EBD Group, BioPharm America™ 2011, to be held at the Westin Boston Waterfront Hotel September 7–9, is poised to be one of the most productive biotech partnering conferences of the year. The event will play host to the largest pharmaceutical and biotech companies in the world, including Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Genentech, Gilead, GlaxoSmithKline, Merck, Novartis, Novo Nordisk, Nycomed, Pfizer, Roche, sanofi-aventis/Genzyme, Shire, and Takeda/Millennium.

"Exploring new partnerships and building strong relationships are some of the key reasons why Shire is attending and sponsoring BioPharm America,” said Deanna Petersen, VP of Business Development at Shire HGT. “As a company dedicated to innovation, it is a great opportunity for us to meet with like-minded organizations and discuss possible collaborations."

With more than 1,000 dealmakers expected, these pharmaceutical firms are sending teams of business development scouts to find new partnering opportunities. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.

“Big pharma participation in BioPharm America continues to grow because they recognize the value the event has for their business,” said Carola Schropp, President of EBD Group. “It’s one of the few times that leading life science decision makers from around the world meet in North America and discuss potential collaborations.”

BioPharm America was specifically designed to help companies form in- or out-licensing agreements and co-development deals, and raise capital. The event features partneringONE®, the industry’s most advanced web-based networking system. With partneringONE, attendees can connect with pharma companies at all times, manage their conference activities in personal agenda files, and search and bookmark companies of interest for easy follow-up.

“Partnering is what drives innovation in the life science industry,” continued Schropp, “and BioPharm America provides the enabling platform for emerging biotech innovators and large pharmaceutical firms to strike deals that accelerate strategic plans.”

BioPharm America is produced by EBD Group in collaboration with MassBio.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world.

Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

About MassBio

MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and healthcare, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

For more information please visit www.massbio.org.



CONTACT:

EBD Group
Constantine Theodoropulos, + 1 760-930-0500
[email protected]

KEYWORDS:   United States  Europe  North America  California  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.